The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Nefrología

• Publication date

  2013-11-13

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.3265/Nefrologia.pre2013.Jul.12091PMID 24158124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications.

  2013cited by this paper
• Expression of FGF23/KLOTHO system in human vascular tissue.

  2013cited by this paper
• Arterial Klotho Expression and FGF23 Effects on Vascular Calcification and Function

  2013cited by this paper
• Fibroblast Growth Factor 23 and Klotho Are Present in the Growth Plate

  2013cited by this paper
• The effects of iron on FGF23-mediated Ca–P metabolism in CKD patients

  2013cited by this paper
• FGF23/Klotho axis: phosphorus, mineral metabolism and beyond.

  2012cited by this paper
• Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

  2012cited by this paper
• Repression of osteocyte Wnt/β‐catenin signaling is an early event in the progression of renal osteodystrophy

  2012cited by this paper
• αKlotho: FGF23 coreceptor and FGF23-regulating hormone.

  2012cited by this paper
• Mechanism of FGF23 processing in fibrous dysplasia

  2012cited by this paper
• Fibroblast growth factor 23: state of the field and future directions.

  2012cited by this paper
• Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study.

  2012cited by this paper
• Calcium deficiency reduces circulating levels of FGF23.

  2012cited by this paper
• Pathophysiology of chronic kidney disease-mineral and bone disorder.

  2012cited by this paper
• FGF23 and mineral metabolism, implications in CKD-MBD.

  2012cited by this paper
• UPDATE ON FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE

  2012cited by this paper
• Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.

  2012cited by this paper
• Circulating αKlotho influences phosphate handling by controlling FGF23 production.

  2012cited by this paper
• Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.

  2011cited by this paper
• Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

  2011cited by this paper
• Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

  2011cited by this paper
• FGF23 induces left ventricular hypertrophy.

  2011cited by this paper
• Fibroblast Growth Factor 23 (FGF23) and Alpha-Klotho Stimulate Osteoblastic MC3T3.E1 Cell Proliferation and Inhibit Mineralization

  2011cited by this paper
• Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study.

  2011cited by this paper
• Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients

  2011cited by this paper
• Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.

  2011cited by this paper
• Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

  2011cited by this paper
• Klotho deficiency causes vascular calcification in chronic kidney disease.

  2011cited by this paper
• Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling

  2011cited by this paper
• Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo.

  2011cited by this paper
• Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice

  2011cited by this paper
• Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients.

  2010cited by this paper
• PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.

  2010cited by this paper
• Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations

  2010cited by this paper
• Fibroblast Growth Factor 23 in Chronic Kidney Disease: Bridging the Gap between Bone Mineral Metabolism and Left Ventricular Hypertrophy

  2010cited by this paper
• Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease.

  2010cited by this paper
• Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

  2010cited by this paper
• Forging forward with 10 burning questions on FGF23 in kidney disease.

  2010cited by this paper
• Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.

  2010cited by this paper
• Recent progress in the treatment of vascular calcification.

  2010cited by this paper
• The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease.

  2010cited by this paper
• Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.

  2009cited by this paper
• Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase.

  2009cited by this paper
• Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia

  2009cited by this paper
• Bone formation regulates circulating concentrations of fibroblast growth factor 23.

  2009cited by this paper
• FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.

  2009cited by this paper
• Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation

  2009cited by this paper
• Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis

  2009cited by this paper
• Novel regulators of Fgf23 expression and mineralization in Hyp bone.

  2009cited by this paper
• Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.

  2009cited by this paper
• Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.

  2009cited by this paper
• Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community.

  2009cited by this paper
• Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

  2008cited by this paper
• Overexpression of Fibroblast Growth Factor 23 Suppresses Osteoblast Differentiation and Matrix Mineralization In Vitro

  2008cited by this paper
• NON‐CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Hypertrophy and Fibrosis in the Cardiomyopathy of Uremia—Beyond Coronary Heart Disease

  2008cited by this paper
• Association of oral calcitriol with improved survival in nondialyzed CKD.

  2008cited by this paper
• Association of activated vitamin D treatment and mortality in chronic kidney disease.

  2008cited by this paper
• Genetic Evidence of Serum Phosphate-Independent Functions of FGF-23 on Bone

  2008cited by this paper
• Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice.

  2007cited by this paper
• Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.

  2007cited by this paper
• Cinacalcet in the Management of Tumor‐Induced Osteomalacia

  2007cited by this paper
• Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans

  2007cited by this paper
• 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism.

  2007cited by this paper
• The parathyroid is a target organ for FGF23 in rats.

  2007cited by this paper
• Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23.

  2007cited by this paper
• Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.

  2007cited by this paper
• Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.

  2007cited by this paper
• Pathogenic role of Fgf23 in Hyp mice.

  2006cited by this paper
• Klotho converts canonical FGF receptor into a specific receptor for FGF23

  2006cited by this paper
• Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.

  2006cited by this paper
• Pathogenic role of Fgf 23 in Hyp mice

  2006cited by this paper
• Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

  2006cited by this paper
• Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism

  2006cited by this paper
• Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

  2006cited by this paper
• Suppression of Aging in Mice by the Hormone Klotho

  2005cited by this paper
• Calcium abnormalities of dialysis patients

  2005cited by this paper
• Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.

  2005cited by this paper
• Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

  2005cited by this paper
• Bone as a source of FGF23: regulation by phosphate?

  2004cited by this paper
• Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.

  2004cited by this paper
• Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis

  2004cited by this paper
• FGF-23 is elevated by chronic hyperphosphatemia.

  2004cited by this paper
• Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

  2004cited by this paper
• Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEX*

  2003cited by this paper
• Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism.

  2003cited by this paper
• FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis

  2003cited by this paper
• Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 Production*

  2003cited by this paper
• Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system.

  2003cited by this paper
• Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

  2003cited by this paper
• Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

  2002cited by this paper
• Severely reduced production of klotho in human chronic renal failure kidney.

  2001cited by this paper
• Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

  2000cited by this paper
• Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism.

  1997cited by this paper
• Mutation of the mouse klotho gene leads to a syndrome resembling ageing

  1997cited by this paper
• 1,25-(OH)2D receptors are decreased in parathyroid glands from chronically uremic dogs.

  1989cited by this paper
• Harrison's Principles of Internal Medicine

  1984cited by this paper

• Interleukin-6 in Natural and Pathophysiological Kidney Aging

  2026cites this paper
• Assessment of quality of life following subtotal parathyroidectomy in patients with secondary hyperparathyroidism resulting from end-stage renal disease: a single-center prospective study in Vietnam

  2025cites this paper
• Major adverse kidney events among chronic kidney disease patients with vitamin D deficiency

  2025cites this paper
• Correlation between glomerular filtration rate and parathyroid hormone

  2025cites this paper
• The Effect of Periodontitis on Fibroblast Growth Factor 23 Levels in Predialysis Chronic Kidney Disease Patients

  2024cites this paper
• Association of fibroblast growth factor-23 among chronic kidney disease patients with mineral bone disease

  2021cites this paper
• Analysis of bone in adenine-induced chronic kidney disease model rats

  2021cites this paper
• Vitamin D and skeletal muscle: A narrative review focusing on chronic kidney disease and dialysis

  2021cites this paper
• Parathyroid Glands in Chronic Kidney Disease

  2020cites this paper
• The Role of the Old and the New Calcimimetic Agents in Chronic Kidney Disease-Mineral and Bone Disorder

  2020cites this paper
• Renal Medicine and Clinical Pharmacy

  2020cites this paper
• Correlation between interdialytic weight gain, left ventricular hypertrophy and FGF- 23 in prevalent hemodialysis patients

  2020cites this paper
• Chronic Kidney Disease and End Stage Renal Disease

  2020cites this paper
• CLINICAL AND BIOCHEMICAL STUDY OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE.

  2018cites this paper
• Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes

  2017cites this paper
• Fibroblast growth factor 23 and cardiovascular disease in chronic kidney disease; new trends

  2017cites this paper
• FGF-23 and Hyperphosphatemia in Dialysis Dependent Chronic Kidney Disease Patients

  2017cites this paper
• Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia

  2017cites this paper
• Chronic Kidney Disease and Hypertensive-Related Complications of Elevated Fibroblast Growth Factor 23

  2017cites this paper
• Role of nitric oxide in glucose-, fructose and galactose-induced increases in intestinal glucose uptake

  2016cites this paper
• In Vitro Effects of Pioglitazone on the Expression of Components of Wnt Signaling Pathway and Markers of Bone Mineralization

  2016cites this paper
• Elevated fibroblast growth factor-23 and risk of cardiovascular disease or mortality in the general population: A meta-analysis.

  2016cites this paper
• Fibroblast growth factor 23 : a potential cause of cardiovascular diseases in chronic kidney disease patients

  2016cites this paper
• Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized Trial

  2015cites this paper
• Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients

  2015cites this paper
• Fgf-23 and vascular calcification in a peritoneal dialysis population with residual renal function

  2015cites this paper
• Rol de FGF23 en la enfermedad renal crónica

  2014cites this paper